Challenges in neoantigen-directed therapeutics
L Lybaert, S Lefever, B Fant, E Smits, B De Geest… - Cancer Cell, 2023 - cell.com
A fundamental prerequisite for the efficacy of cancer immunotherapy is the presence of
functional, antigen-specific T cells within the tumor. Neoantigen-directed therapy is a …
functional, antigen-specific T cells within the tumor. Neoantigen-directed therapy is a …
[HTML][HTML] Technological advances in cancer immunity: from immunogenomics to single-cell analysis and artificial intelligence
Y Xu, GH Su, D Ma, Y Xiao, ZM Shao… - Signal Transduction and …, 2021 - nature.com
Immunotherapies play critical roles in cancer treatment. However, given that only a few
patients respond to immune checkpoint blockades and other immunotherapeutic strategies …
patients respond to immune checkpoint blockades and other immunotherapeutic strategies …
[HTML][HTML] Persistent mutation burden drives sustained anti-tumor immune responses
Tumor mutation burden is an imperfect proxy of tumor foreignness and has therefore failed
to consistently demonstrate clinical utility in predicting responses in the context of …
to consistently demonstrate clinical utility in predicting responses in the context of …
NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand …
Major histocompatibility complex (MHC) molecules are expressed on the cell surface, where
they present peptides to T cells, which gives them a key role in the development of T-cell …
they present peptides to T cells, which gives them a key role in the development of T-cell …
Human leukocyte antigen susceptibility map for severe acute respiratory syndrome coronavirus 2
Genetic variability across the three major histocompatibility complex (MHC) class I genes
(human leukocyte antigen A [HLA-A],-B, and-C genes) may affect susceptibility to and …
(human leukocyte antigen A [HLA-A],-B, and-C genes) may affect susceptibility to and …
[HTML][HTML] A transformer-based model to predict peptide–HLA class I binding and optimize mutated peptides for vaccine design
Human leukocyte antigen (HLA) can recognize and bind foreign peptides to present them to
specialized immune cells, then initiate an immune response. Computational prediction of the …
specialized immune cells, then initiate an immune response. Computational prediction of the …
Improved prediction of MHC II antigen presentation through integration and motif deconvolution of mass spectrometry MHC eluted ligand data
B Reynisson, C Barra, S Kaabinejadian… - Journal of proteome …, 2020 - ACS Publications
Major histocompatibility complex II (MHC II) molecules play a vital role in the onset and
control of cellular immunity. In a highly selective process, MHC II presents peptides derived …
control of cellular immunity. In a highly selective process, MHC II presents peptides derived …
[HTML][HTML] Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial
Mesothelioma is a rare and fatal cancer with limited therapeutic options until the recent
approval of combination immune checkpoint blockade. Here we report the results of the …
approval of combination immune checkpoint blockade. Here we report the results of the …
Targeting public neoantigens for cancer immunotherapy
Several current immunotherapy approaches target private neoantigens derived from
mutations that are unique to individual patients' tumors. However, immunotherapeutic …
mutations that are unique to individual patients' tumors. However, immunotherapeutic …
Deep neural networks predict class I major histocompatibility complex epitope presentation and transfer learn neoepitope immunogenicity
Identifying neoepitopes that elicit an adaptive immune response is a major bottleneck to
developing personalized cancer vaccines. Experimental validation of candidate …
developing personalized cancer vaccines. Experimental validation of candidate …